81 research outputs found

    First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

    Get PDF
    Background: In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to tamoxifen as first-line endocrine therapy in postmenopausal women with advanced breast cancer. Patients and methods: Two hundred twelve eligible patients were randomized to receive tamoxifen 20 mg daily, or fadrozole 1 mg twice daily orally until disease progression or the advent of undue toxicity. The treatments were to be discontinued upon disease progression. Results: Prognostic factors were well balanced between the treatment groups, except for sites of metastatic disease. Fadrozole-treated patients had significantly more visceral, especially liver, involvement and less bone-dominant disease. Response rates for fadrozole and tamoxifen were similar, 20% and 27% (95% Confidence Limits (CL): 13%-29% and 21%-35%), respectively. Time to treatment failure was longer in patients randomized to tamoxifen (8.5 months for tamoxifen vs. 6.1 months for fadrozole), but did not reach statistical significance after adjustment for prognostic factors (P=0.09). Fadrozole, for which a significantly lower percentage of clinically relevant toxic effects (WHO toxicity gradeÄł2) was recorded (27% vs. 13% respectively; P=0.009), was better tolerated than tamoxifen. Severe cardiovascular events including 3 fatalities were seen only in patients treated with tamoxifen. Eighty-two patients crossed over to tamoxifen and 66 patients to fadrozole. Crossover endocrine therapy led to response or stable disease in 64% of the patients. The overall survival times of the two treatment groups were similar. Conclusions: Fadrozole and tamoxifen showed similar efficacy as first-line treatments in postmenopausal patients with advanced breast cancer. Fadrozole was significantly better tolerated and may therefore be an appropriate alternative to tamoxifen, especially for patients predisposed to thromboembolic event

    Long-term observations minus background monitoring of ground-based brightness temperatures from a microwave radiometer network

    Get PDF
    Abstract. Ground-based microwave radiometers (MWRs) offer the capability to provide continuous, high-temporal-resolution observations of the atmospheric thermodynamic state in the planetary boundary layer (PBL) with low maintenance. This makes MWR an ideal instrument to supplement radiosonde and satellite observations when initializing numerical weather prediction (NWP) models through data assimilation. State-of-the-art data assimilation systems (e.g. variational schemes) require an accurate representation of the differences between model (background) and observations, which are then weighted by their respective errors to provide the best analysis of the true atmospheric state. In this perspective, one source of information is contained in the statistics of the differences between observations and their background counterparts (O–B). Monitoring of O–B statistics is crucial to detect and remove systematic errors coming from the measurements, the observation operator, and/or the NWP model. This work illustrates a 1-year O–B analysis for MWR observations in clear-sky conditions for an European-wide network of six MWRs. Observations include MWR brightness temperatures (TB) measured by the two most common types of MWR instruments. Background profiles are extracted from the French convective-scale model AROME-France before being converted into TB. The observation operator used to map atmospheric profiles into TB is the fast radiative transfer model RTTOV-gb. It is shown that O–B monitoring can effectively detect instrument malfunctions. O–B statistics (bias, standard deviation, and root mean square) for water vapour channels (22.24–30.0 GHz) are quite consistent for all the instrumental sites, decreasing from the 22.24 GHz line centre (â€‰âˆŒâ€‰â€Ż2–2.5 K) towards the high-frequency wing (â€‰âˆŒâ€‰â€Ż0.8–1.3 K). Statistics for zenith and lower-elevation observations show a similar trend, though values increase with increasing air mass. O–B statistics for temperature channels show different behaviour for relatively transparent (51–53 GHz) and opaque channels (54–58 GHz). Opaque channels show lower uncertainties (< 0.8–0.9 K) and little variation with elevation angle. Transparent channels show larger biases (â€‰âˆŒâ€‰â€Ż2–3 K) with relatively low standard deviations (â€‰âˆŒâ€‰â€Ż1–1.5 K). The observations minus analysis TB statistics are similar to the O–B statistics, suggesting a possible improvement to be expected by assimilating MWR TB into NWP models. Lastly, the O–B TB differences have been evaluated to verify the normal-distribution hypothesis underlying variational and ensemble Kalman filter-based DA systems. Absolute values of excess kurtosis and skewness are generally within 1 and 0.5, respectively, for all instrumental sites, demonstrating O–B normal distribution for most of the channels and elevations angles

    Finishing the euchromatic sequence of the human genome

    Get PDF
    The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∌99% of the euchromatic genome and is accurate to an error rate of ∌1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
    • 

    corecore